Nogron (Temozolomide)

Temozolomide is a pro‑drug that converts to MTIC, which methylates DNA at the O6 and N7 positions of guanine. This methylation creates mismatched base pairs and DNA strand breaks, leading to cell‑cycle arrest and apoptosis, particularly in tumor cells lacking the MGMT repair enzyme.

The exact dosing regimen is determined by the prescribing physician based on the patient’s diagnosis, body surface area, renal and hepatic function, and treatment protocol. Doses are individualized and should follow established clinical guidelines.

Temozolomide is contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while receiving therapy.

To request Nogron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to temozolomide is carmustine, another alkylating agent. Temozolomide offers oral administration, better blood‑brain barrier penetration, and a more favorable toxicity profile, whereas carmustine is given intravenously and is associated with higher rates of pulmonary toxicity.

Store Nogron tablets at ambient temperature, below 25 °C, in the original blister pack or bottle. Keep the product away from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nogron is taken orally, usually with food or a light snack to reduce gastrointestinal irritation. The tablets should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious adverse effects include profound myelosuppression leading to neutropenia or thrombocytopenia, severe infections such as sepsis, and hepatic toxicity. Patients should be monitored closely for signs of infection, bleeding, or liver dysfunction throughout therapy.

Temozolomide is contraindicated in patients with known hypersensitivity to the drug, in pregnant or nursing women, and in individuals with severe bone‑marrow suppression or uncontrolled liver disease. Caution is also advised for patients receiving other myelosuppressive treatments.